Welcome to our dedicated page for InMed Pharmaceuticals SEC filings (Ticker: INM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
InMed Pharmaceuticals Inc. filings document the regulatory record of a British Columbia pharmaceutical issuer with common shares listed on Nasdaq under INM. Its disclosures cover small-molecule drug development programs targeting CB1 and CB2 receptors, including INM-901 for Alzheimer's disease and programs in ocular and dermatological indications.
Recent filings include Current Reports on Form 8-K for financial results and business updates, material definitive agreements involving preferred investment options, at-the-market offering documentation, Nasdaq continued-listing compliance, shareholder voting matters, and exit or disposal activities related to BayMedica. The company's formal reports also address risk factors, capital structure, governance, and clinical or regulatory disclosures.
InMed Pharmaceuticals Inc. (INM) disclosed that on September 16, 2026 it received a Nasdaq notice that the company is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2,500,000 in shareholders’ equity for continued listing on The Nasdaq Capital Market. InMed reported $1,075,007 of shareholders’ equity as of June 30, 2026, mainly due to transaction-related expenses for its planned merger with Mentari Therapeutics, Inc., as well as costs from winding down BayMedica, higher general and administrative expenses, intangible asset impairments and ongoing operating losses.
The company expects that completing its merger with Mentari, together with Mentari’s pre-closing financing, will provide the combined company with approximately $490.0 million in aggregate gross proceeds, including $50.0 million from Mentari convertible notes, and believes this will restore compliance with Nasdaq’s equity requirement. InMed’s share price as of September 18, 2026 is reported to be about $0.68 higher, or roughly 99.8% above the level before the initial merger announcement. InMed has 45 days, until November 2, 2026, to submit a compliance plan, and may receive up to 180 days, until March 15, 2027, to regain compliance, though there is no assurance the plan will be accepted or that any appeal of a delisting decision would succeed.
InMed Pharmaceuticals Inc. (INM) reported that private investment funds managed by ADAR1 Capital Management, LLC, a ten percent owner, made open-market purchases of a total of 91,101 common shares on September 14–16, 2026, at weighted average prices around $1.29 per share.
The shares are held by ADAR1-managed funds and may be deemed indirectly beneficially owned by ADAR1 Capital Management, LLC and Daniel Schneeberger, who each disclaim beneficial ownership except to the extent of any pecuniary interest. No Rule 10b5-1 trading plan is reported.
InMed Pharmaceuticals Inc. (symbol: INM) is the issuer of record for a Form S-4/A filing submitted to the SEC.
InMed Pharmaceuticals Inc. (INM) reported fiscal 2026 results and detailed progress on its proposed merger with privately held Mentari Therapeutics, Inc. In connection with the merger, Mentari announced an oversubscribed $290 million private placement in May 2026 and an additional $200 million private placement in July 2026, bringing expected aggregate pre-closing financing to approximately $490 million, which is expected to extend the combined company’s cash runway into 2029 and through Phase 2a readouts for Mentari’s two PACAP-targeted lead migraine programs.
Legacy InMed shareholders are expected to receive Contingent Value Rights tied to potential future monetization of INM-901, INM-089 and INM-755, while InMed advances INM-901 after a pre-IND FDA meeting and seeks strategic transactions for all three programs. InMed decided to discontinue its BayMedica subsidiary, which recorded $3.2 million in sales from discontinued operations versus $5.0 million a year earlier, and has wound down its activities.
For the year ended June 30, 2026, InMed recorded a net loss attributable to common shareholders of $13.0 million versus $8.2 million in 2025, driven by higher general and administrative and research and development expenses and asset impairments, including $1.46 million of intangible and $0.19 million of equipment impairments. Total operating cash outflow was $8.6 million, and cash, cash equivalents and short-term investments declined to $2.2 million at June 30, 2026, with total assets falling to $3.0 million and shareholders’ equity to $1.1 million. The merger remains on track to close in the fourth quarter of 2026, subject to customary conditions and effectiveness of the Form S-4.
InMed Pharmaceuticals Inc. (INM) reported a sharp deterioration in its financial position for the year ended June 30, 2026, while winding down its only revenue-generating business. Total assets fell to $3.0 million from $15.6 million, and shareholders’ equity declined to $1.1 million from $13.4 million.
The company recorded a net loss of $12.6 million, including a $1.2 million loss from discontinued BayMedica operations, and recognized $1.46 million of intangible asset impairments plus $189,225 of equipment impairment. Cash and cash equivalents were $2.2 million, and the auditor and management both state that these conditions raise substantial doubt about InMed’s ability to continue as a going concern.
On March 4, 2026, the board approved the wind-down and exit of BayMedica’s commercial operations; as of June 30, 2026 this was substantially completed, eliminating the company’s commercial revenue stream. Remaining activities focus on preclinical development of INM-901 for Alzheimer’s disease, INM-089 for dry AMD, and INM-755 cream, but InMed does not currently intend to devote significant resources to these programs without obtaining additional financing.
InMed Pharmaceuticals Inc. has a significant shareholder disclosure from Ikarian Capital, LLC and Neil Shahrestani. They jointly report beneficial ownership of 137,634 Common Shares of InMed Pharmaceuticals Inc., representing 4.2% of the Common Shares outstanding.
The shares are held through Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts over which Ikarian Capital has investment discretion. The reporting persons have shared voting and dispositive power over 137,634 shares and no sole power. The 4.2% figure is based on 3,314,063 Common Shares outstanding as of May 4, 2026, as disclosed by the issuer. The reporting parties include standard disclaimers regarding the extent of their beneficial ownership and group status.
InMed Pharmaceuticals Inc. plans to acquire 100% of Mentari Therapeutics, Inc. through a reverse triangular merger, after which Mentari will become a wholly owned subsidiary and then merge into another InMed subsidiary. The transaction is intended to be tax-free.
Post-closing, InMed holders are expected to own about 1.15% of the combined company, Mentari holders about 22.63%, an initial private placement about 52.51% and a second private placement about 23.70%, implying a total transaction value of roughly $621 million. Concurrent financings include a $290 million initial tranche and a $200 million second tranche, both closing immediately before the merger.
An estimated 601,195,812 shares of common stock of the combined company will be outstanding on an as-converted/as-exercised basis, including 6,926,398 InMed shares representing 1.15%. Proceeds are expected to fund Mentari’s migraine-prevention pipeline (programs MT-001, MT-002, MT-003 and others) with anticipated Phase 1 and Phase 2a data and a projected cash runway into 2029. Closing is subject to shareholder approvals, Form S-4 effectiveness, Nasdaq listing and other customary conditions, with management and the board to be led by Mentari. Key insiders will be subject to a 180-day lock-up.
InMed Pharmaceuticals Inc. describes an amendment to Mentari Therapeutics’ pre-closing financing tied to their pending merger. On July 22, 2026, Mentari and certain original and new investors agreed to purchase an additional $200 million of common stock and/or pre-funded warrants immediately before the first merger effective time.
The purchase price for the additional shares equals 152.80% of the price paid by original investors, with additional pre-funded warrants priced at that amount minus $0.0001. The expanded financing is expected to extend Mentari’s cash runway into 2029 and support Phase 2a readouts for two PACAP-targeted migraine programs, including MT-002. Based on the merger exchange ratio, pre‑merger Mentari stockholders are expected to own about 98.85% of the combined company and pre‑merger InMed shareholders about 1.15%, with approximately 601,195,812 common shares outstanding on an as-converted / as-exercised basis after completion.
InMed Pharmaceuticals describes an amendment to Mentari Therapeutics’ pre-closing financing tied to their pending merger. Under Amendment No. 1 to the Securities Purchase Agreement, certain original and new investors agreed to purchase an additional $200 million of Mentari common stock and pre-funded warrants immediately prior to the first merger effective time.
The Additional Shares are priced at 152.80% of the per-share price paid by the original investors, with pre-funded warrants priced at that amount minus $0.0001. This expanded Pre-Closing Financing is expected to extend Mentari’s cash runway into 2029, through Phase 2a readouts for its two PACAP-targeted lead migraine programs, and to support its broader migraine prevention pipeline. Based on the merger exchange ratio, pre-Merger Mentari stockholders are expected to own approximately 98.85% of the combined company and pre-Merger InMed shareholders about 1.15%, with total as-converted and as-exercised common shares around 601,195,812.
InMed Pharmaceuticals Inc. describes a proposed merger with Mentari Therapeutics, under which two InMed merger subsidiaries will combine with Mentari in a two-step structure, leaving an InMed subsidiary as the surviving entity. Completion is subject to conditions in the Merger Agreement, including shareholder approvals and effectiveness of a Form S-4 registration statement.
Mentari has appointed Greg Divis, former Avadel Pharmaceuticals CEO, as Chief Executive Officer and board member, effective July 20, 2026. Mentari is developing migraine-prevention therapies MT-001, an anti-PACAP antibody, and MT-002, an anti-PACAP/anti-CGRP bispecific antibody, with regulatory filings planned in MY 2026 and Q1 2027, respectively. Extensive forward-looking statements language highlights risks such as failure to close the merger, financing risks, redomestication and reverse stock split steps, and Nasdaq continued-listing requirements.